Many European Cancer Drugs Offer No Added Benefit Many European Cancer Drugs Offer No Added Benefit

Two fifths of oncology drugs approved by the EMA over the past 25 years don ' t offer an added benefit, while their costs may be burdening health systems.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news